department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Xiidra · pharmadog

pharmadog
drugs
Xiidra

drug

patient view →

lifitegrast

Marketedupdated 2mo ago

by $BLCO Bausch & Lomb Corp

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Xiidra

generic

lifitegrast

indication

Keratoconjunctivitis Sicca (Dry Eye)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 15, 2029

~2.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (10)

Dec 18, 2033formulationUS 11058677
Jul 25, 2033formulationUS 9085553
Nov 12, 2030formulationUS 89275744.4y
Oct 21, 2030formulationUS 93530884.3y
Oct 21, 2030compositionUS 98901414.3y
May 9, 2029method-of-use (U-1880)US 81686552.8y
Apr 15, 2029formulationUS 83677012.8y
Apr 15, 2029method-of-use (U-1900)US 94470772.8y
May 17, 2026compositionUS 8084047
May 17, 2026method-of-use (U-1880)US 8592450

Data sources

ClinicalTrials.gov

last refreshed 43m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying lifitegrast

phase4This is a Single Center, Open-label Prospective Study to Evaluate the Effect of Xiidra® (Lifitegrast Ophthalmic Solution 5.0%) on Tear Film Biomarkers in Dry Eyenot yet recruitingn=36
—Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medicationsrecruitingn=75
phase2A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Diseaserecruitingn=423
phase3A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Diseasewithdrawn
phase4A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatmentrecruitingn=350
phase1Lifitegrast Eye Drops in Healthy Subjects：Phase I Studycompletedn=24
phase2A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Diseasecompletedn=292
phase2A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Diseasecompletedn=349

more trials →